Sofosbuvir，Velpatasvir and Voxilaprevir
- Generic Name
- Sofosbuvir，Velpatasvir and Voxilaprevir
- Indication
用于治疗既往接受过含直接抗病毒药物（DAA）方案、无肝硬化或伴代偿性肝硬化（Child-Pugh A）的成人慢性丙型肝炎病毒（HCV）感染
Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
Phase 4
- Conditions
- Hepatitis CCirrhosis
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05467826
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
- Conditions
- Hepatitis C Virus InfectionAdherence, TreatmentEffect of DrugTreatment Side Effects
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05092074
- Locations
- 🇨🇳
St. Martin De Porres Hospital, Chiayi City, Taiwan
🇨🇳Chi-Mei Medical Center, Liouying, Liuying, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
Phase 4
Completed
- Conditions
- Hepatitis CTransplantation Disease Transmission
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 122
- Registration Number
- NCT03619837
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Baylor University Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 77
- Registration Number
- NCT02745535
- Locations
- 🇺🇸
Institute of Human Virology, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath